Summary of characteristics and clinical endpoints of the Singapore trial evaluating the combination of chemotherapy and adoptive T-cell therapy in NPC

ItemsSingapore trial
 Key eligibility criteriaTreatment-naïve recurrent/metastatic EBV-positive NPC
 Experimental regimenChemotherapy+EBV-CTLs: Gemcitabine 1000 mg/m2, and carboplatin (AUC 2) (days 1, 8 and 15) q4wks for 4 cycles, followed by EBV-CTL 1 × 108 cells/m2 on weeks 0, 2, 8, 16, 24, and 32
 Sample size35
Clinical endpoints
 Median follow-up, months29.9
 ORR (%)71.5
 CR (%)8.6
 PR (%)62.9
 SD (%)28.6
 PD (%)0
 All grade AEs (%)NR
 Grade 3–5 AEs (%)NR

Abbreviations: AUC area under the curve, CR complete response, EBV Epstein-Barr virus, EBV-CTLs EBV-specific cytotoxic T lymphocytes, NPC nasopharyngeal carcinoma, NR not reported, ORR objective response rate, q4wks every 4 weeks, PD progressive disease, PR partial response, SD stable disease